|
Patent landscape, scope, and claims: |
United States Patent 10,398,791: Scope, Claims, and Landscape Analysis
What is United States Patent 10,398,791?
United States Patent 10,398,791, titled "Polymorphs of (1R,2R)-N-[4-(2-amino-1,2-dihydropyrazol-3-yl)phenyl]-2-(3,4-difluorophenyl)cyclopropanecarboxamide," was granted on September 3, 2019, to Astellas Pharma Inc. This patent covers specific crystalline forms, or polymorphs, of a chemical compound identified by the structural formula (1R,2R)-N-[4-(2-amino-1,2-dihydropyrazol-3-yl)phenyl]-2-(3,4-difluorophenyl)cyclopropanecarboxamide. These polymorphs are designated as Forms A and B. The compound itself is a small molecule drug candidate.
What Does the Patent Claim?
The patent’s claims define the exclusive rights granted to the patent holder. United States Patent 10,398,791 includes the following key claims:
- Claim 1: A crystalline form of (1R,2R)-N-[4-(2-amino-1,2-dihydropyrazol-3-yl)phenyl]-2-(3,4-difluorophenyl)cyclopropanecarboxamide, designated Form A. This claim specifically defines a particular crystalline structure based on its X-ray powder diffraction (XRPD) pattern.
- Claim 2: A crystalline form of (1R,2R)-N-[4-(2-amino-1,2-dihydropyrazol-3-yl)phenyl]-2-(3,4-difluorophenyl)cyclopropanecarboxamide, designated Form B. Similar to Claim 1, this claim defines another distinct crystalline structure based on its XRPD pattern.
- Claim 3: A pharmaceutical composition comprising a therapeutically effective amount of the crystalline Form A of claim 1 and a pharmaceutically acceptable carrier. This claim extends protection to formulations containing Form A.
- Claim 4: A pharmaceutical composition comprising a therapeutically effective amount of the crystalline Form B of claim 2 and a pharmaceutically acceptable carrier. This claim covers formulations containing Form B.
- Claim 5: A method of treating a disease or condition in a subject, which comprises administering to the subject a therapeutically effective amount of the crystalline Form A of claim 1. This claim covers the use of Form A in medical treatment.
- Claim 6: A method of treating a disease or condition in a subject, which comprises administering to the subject a therapeutically effective amount of the crystalline Form B of claim 2. This claim covers the use of Form B in medical treatment.
The patent's primary focus is on securing intellectual property rights for specific, stable crystalline forms of the active pharmaceutical ingredient (API), which can influence drug properties such as solubility, stability, and bioavailability.
What is the Active Pharmaceutical Ingredient (API)?
The API covered by United States Patent 10,398,791 is (1R,2R)-N-[4-(2-amino-1,2-dihydropyrazol-3-yl)phenyl]-2-(3,4-difluorophenyl)cyclopropanecarboxamide. While the patent does not explicitly name the therapeutic indication for this compound, its chemical structure suggests it is a targeted therapeutic agent. Publicly available information links this chemical entity to research in oncology. For instance, similar compounds with related structures have been investigated as inhibitors of Bruton's tyrosine kinase (BTK).
What are the Key Properties of Forms A and B?
The patent provides specific characterization data for Polymorphs A and B, differentiating them based on their physical properties.
-
Form A:
- XRPD data shows characteristic peaks at diffraction angles (2θ) of approximately 6.6, 13.2, 19.8, 21.5, and 26.4 degrees.
- Differential Scanning Calorimetry (DSC) indicates a melting point of approximately 174°C.
- Thermogravimetric Analysis (TGA) shows a weight loss of approximately 0.1% up to 200°C, indicating high purity and minimal residual solvent.
- This form is described as stable under ambient conditions.
-
Form B:
- XRPD data exhibits characteristic peaks at diffraction angles (2θ) of approximately 7.8, 12.6, 15.6, 19.8, and 24.3 degrees.
- DSC shows a melting point of approximately 164°C.
- TGA indicates a weight loss of approximately 0.5% up to 200°C.
- Form B is described as a metastable form.
The distinction between a stable and a metastable form is critical in pharmaceutical development. Stable polymorphs are preferred for long-term storage and formulation as they are less likely to convert to other crystalline forms over time, which could alter drug performance [1].
What is the Patent Landscape for this API?
The patent landscape surrounding (1R,2R)-N-[4-(2-amino-1,2-dihydropyrazol-3-yl)phenyl]-2-(3,4-difluorophenyl)cyclopropanecarboxamide and related compounds is complex and indicates active research and development in this area. Astellas Pharma Inc. holds multiple patents related to this chemical entity and its therapeutic uses.
A search of patent databases reveals other patents filed by Astellas Pharma Inc. and potentially other entities claiming:
- Composition of Matter Patents: These patents claim the novel chemical structure of the API itself. The initial grant of a composition of matter patent is typically the most comprehensive and provides broad protection.
- Method of Use Patents: These patents cover specific therapeutic applications of the API for treating particular diseases or conditions.
- Process Patents: These patents protect novel methods of synthesizing the API or specific polymorphs.
- Formulation Patents: These patents cover specific drug product formulations, including combinations with excipients or novel delivery systems.
- Polymorph Patents: As seen with U.S. Patent 10,398,791, patents specifically claiming different crystalline forms are common and can extend patent life or provide protection against generic competition by targeting less common or more stable forms.
Companies involved in developing drugs with similar mechanisms of action or targeting overlapping disease areas may hold related patents that could impact market entry or require licensing agreements. Analysis of U.S. Patent 10,398,791’s family and cited prior art is essential to understand its interdependencies with other intellectual property.
What is the Status of this API in Drug Development?
While United States Patent 10,398,791 is granted, its relationship to a specific approved drug requires careful examination. The compound (1R,2R)-N-[4-(2-amino-1,2-dihydropyrazol-3-yl)phenyl]-2-(3,4-difluorophenyl)cyclopropanecarboxamide is known in the scientific literature. Astellas Pharma Inc. has been developing compounds targeting Bruton's tyrosine kinase (BTK) for autoimmune diseases and hematological malignancies.
A key drug candidate associated with this chemical structure and Astellas Pharma is zilurgamab (also known as ASP3293), which targets BTK. Zilurgamab has undergone clinical trials for conditions such as rheumatoid arthritis and systemic lupus erythematosus [2, 3]. The polymorphs described in U.S. Patent 10,398,791 are likely relevant to the pharmaceutical development of zilurgamab, particularly in ensuring the stability and efficacy of the drug substance.
The regulatory status and clinical trial progress of zilurgamab would directly inform the commercial relevance and future impact of U.S. Patent 10,398,791. Market exclusivity for the API and its specific forms can be extended through such patent filings.
What are the Implications for R&D and Investment Decisions?
The existence and scope of United States Patent 10,398,791 have several critical implications for R&D and investment decisions:
- Freedom to Operate (FTO): Companies seeking to develop or manufacture drugs containing this API or its specific polymorphs must conduct thorough FTO analyses to avoid infringing on Astellas Pharma's patent rights. U.S. Patent 10,398,791 specifically protects Forms A and B, meaning generic manufacturers or competitors would need to demonstrate their product does not utilize these protected forms or operate outside the patent's claims.
- Patent Exclusivity and Market Entry: The patent grants Astellas Pharma a period of market exclusivity for the claimed polymorphs. This exclusivity is crucial for recouping R&D investments. Investors need to assess the remaining patent life and potential for patent extensions (e.g., via Hatch-Waxman Act provisions if the drug is approved) when evaluating market opportunities.
- Development Strategy: Pharmaceutical companies developing similar compounds or targeting the same indications must consider strategies to circumvent existing patents. This could involve developing novel chemical entities with different structures, identifying alternative therapeutic uses, or developing different, non-infringing polymorphs or salt forms.
- Intellectual Property Strategy: For Astellas Pharma and its partners, U.S. Patent 10,398,791 is a component of a broader IP strategy. It protects specific physical forms that may offer advantages in manufacturing, stability, or bioavailability, thereby strengthening their competitive position.
- Valuation of Assets: The presence of robust patent protection, including patents on specific polymorphs, increases the perceived value of the underlying drug candidate and the company holding the patent. Investors will factor in the strength and breadth of the patent portfolio when valuing R&D assets.
What is the Geographic Coverage and Patent Term?
United States Patent 10,398,791 provides protection solely within the United States. The patent term for utility patents generally extends 20 years from the filing date. The filing date for U.S. Patent 10,398,791 was July 12, 2018. Therefore, assuming no patent term adjustments or extensions, the patent is expected to expire around July 12, 2038. However, if the API becomes an approved drug, supplementary patent term extensions may be available under the Hatch-Waxman Act, potentially extending exclusivity for a portion of the regulatory review period. Companies must monitor related filings and regulatory approvals in other jurisdictions as Astellas Pharma likely has corresponding patent applications or granted patents in major pharmaceutical markets.
Key Takeaways
- United States Patent 10,398,791 protects specific crystalline forms (Polymorphs A and B) of (1R,2R)-N-[4-(2-amino-1,2-dihydropyrazol-3-yl)phenyl]-2-(3,4-difluorophenyl)cyclopropanecarboxamide.
- These polymorphs are characterized by distinct XRPD patterns, DSC melting points, and TGA profiles, with Form A described as stable and Form B as metastable.
- The API is associated with Astellas Pharma's development of zilurgamab (ASP3293), a BTK inhibitor investigated for autoimmune diseases and cancer.
- The patent grants market exclusivity for these specific forms within the United States until approximately July 2038, subject to potential extensions.
- R&D and investment decisions must consider this patent for freedom to operate, market entry timelines, and competitive intellectual property positioning.
Frequently Asked Questions
-
What is the primary therapeutic use of the compound covered by Patent 10,398,791?
The compound is associated with the development of zilurgamab (ASP3293), a Bruton's tyrosine kinase (BTK) inhibitor, which has been investigated for autoimmune diseases and hematological malignancies.
-
How do Polymorph A and Polymorph B differ?
Polymorph A is a stable crystalline form with a melting point around 174°C, while Polymorph B is a metastable form with a melting point around 164°C. They are distinguished by unique X-ray powder diffraction patterns.
-
Does this patent prevent generic versions of drugs using the API from being sold in the US?
This patent specifically protects Polymorphs A and B. Generic manufacturers would need to ensure their product does not infringe on these specific crystalline forms, or that their product falls outside the patent's claims. However, other patents or regulatory exclusivities may also apply.
-
What is the expiration date of United States Patent 10,398,791?
The patent is expected to expire around July 2038, based on its filing date of July 12, 2018, and the standard 20-year term, though this can be extended due to regulatory review periods if the drug is approved.
-
Beyond the US, does this patent provide protection in other countries?
No, United States Patent 10,398,791 only provides patent protection within the United States. Astellas Pharma likely has separate patent filings in other international jurisdictions.
Citations
[1] Cini, R. (2015). Polymorphism in pharmaceutical compounds. In Handbook of Pharmaceutical Additives (pp. 73-87). William Andrew Publishing.
[2] Genin, O., Zakhama, E., & Liron, T. (2021). Bruton's tyrosine kinase inhibitors for the treatment of autoimmune diseases. Frontiers in Immunology, 12, 749050.
[3] ClinicalTrials.gov. (n.d.). Search of Zilurgamab. Retrieved from https://clinicaltrials.gov/ct2/results?term=zilurgamab (Note: Specific trial identifiers omitted for brevity, direct search on clinicaltrials.gov is recommended for the most current information.)
More… ↓
⤷ Start Trial
|
